GlassScriptPhysician profile
Ujjala Moolani
NPI 1528221421
$3,174.90
in general payments reported to CMS, 2019-2025
21 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.00 · 2021: $43.31 · 2022: $194 · 2023: $325 · 2024: $2,290 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,400 · Food and Beverage: $1,108 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,400.00 |
| Food and Beverage | $1,108.47 |
| Education | $359.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,027.18 | 2024 | Krystexxa |
| Aurinia Pharma U.S., INC. | $242.30 | 2023-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $139.04 | 2022-2025 | |
| Horizon Therapeutics Plc | $129.45 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $91.98 | 2024 | Xarelto |
| Nxstage Medical, INC. | $75.17 | 2023 | Nxstage System One |
| Baxter Healthcare | $70.00 | 2019 | |
| Merck Sharp & Dohme LLC | $69.45 | 2021-2025 | Keytruda, Welireg |
| Novo Nordisk INC | $40.55 | 2022 | |
| Janssen Biotech, INC. | $36.37 | 2025 | Tecvayli, Darzalex |
| Pharmaessentia USA Corporation | $33.50 | 2025 | Besremi |
| Novartis Pharmaceuticals Corporation | $31.56 | 2025 | |
| Daiichi Sankyo INC. | $29.56 | 2025 | Enhertu |
| Tersera Therapeutics LLC | $28.13 | 2024 | Xermelo |
| Blueprint Medicines Corporation | $27.14 | 2025 | Ayvakit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $20.56 | 2021 | |
| Calliditas Therapeutics US INC. | $20.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.30 | 2025 | Jardiance |
| Servier Pharmaceuticals LLC | $16.53 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2025 | Opdualag |
| Alnylam Pharmaceuticals INC. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ujjala Moolani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.